Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas

Abstract

The dynamics of PD-L1 expression are poorly understood over the development of lung adenocarcinomas from pre-invasive lesions to fully invasive carcinomas. Given the importance of PD-L1 expression for the selection of patients to receive immunotherapy in the metastatic setting and possibly in the neoadjuvant setting, we sought to evaluate the agreement of PD-L1 expression in invasive and lepidic components of resected tumor specimens. We stained 86 adenocarcinomas for PD-L1 using the SP263 clone. We assessed the agreement of PD-L1 expression by tumor cells and immune cells between lepidic and invasive components. When both lepidic and invasive components were considered, PD-L1 positive immune cells and tumor cells were observed in 50 (58.1%) and 18 (20.9%) samples, respectively, using a ≥ 1% PD-L1 expression cutoff. Using a ≥ 1% cutoff for PD-L1 expression, positively stained tumor cells were observed in 11 (13%) lepidic and 15 (17%) invasive patterns, with agreement in 76 (88%) specimens and disagreement in 10 (12%) specimens (ĸ = 0.549). At ≥ 1% PD-L1 expression cutoff, PD-L1 positive immune cells were observed in 31 (35%) lepidic and 32 (37%) invasive patterns with an agreement of PD-L1 expression in 49 (57%) specimens and disagreement in 37 (43%) specimens (ĸ = 0.073). In our study of early stage adenocarcinomas of the lung, there was poor agreement in PD-L1 expression between paired invasive and lepidic components of tumors. Our data suggest that the non-invasive tumor components may not be as immunostimulatory as the invasive components, resulting in less adaptive expression of PD-L1.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Langer CJ et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497–1508

    CAS  Article  Google Scholar 

  2. 2.

    Paz-Ares L et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379(21):2040–2051

    CAS  Article  Google Scholar 

  3. 3.

    Reck M et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

    CAS  Article  Google Scholar 

  4. 4.

    Antonia SJ et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350

    CAS  Article  Google Scholar 

  5. 5.

    Kim MY et al (2015) Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 88(1):24–33

    Article  Google Scholar 

  6. 6.

    Kluger HM et al (2015) Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 21(13):3052–3060

    CAS  Article  Google Scholar 

  7. 7.

    Madore J et al (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–253

    CAS  Article  Google Scholar 

  8. 8.

    Lee SM et al (2013) Invasive pulmonary adenocarcinomas versus preinvasive lesions appearing as ground-glass nodules: differentiation by using CT features. Radiology 268(1):265–273

    Article  Google Scholar 

  9. 9.

    Jones KD (2013) Whence lepidic?: the history of a Canadian neologism. Arch Pathol Lab Med 137(12):1822–1824

    Article  Google Scholar 

  10. 10.

    Travis WD et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260

    Article  Google Scholar 

  11. 11.

    Araki K et al (2014) Excellent prognosis of lepidic-predominant lung adenocarcinoma: low incidence of lymphatic vessel invasion as a key factor. Anticancer Res 34(6):3153–3156

    PubMed  Google Scholar 

  12. 12.

    Xu L, Tavora F, Burke A (2013) Histologic features associated with metastatic potential in invasive adenocarcinomas of the lung. Am J Surg Pathol 37(7):1100–1108

    Article  Google Scholar 

  13. 13.

    Yanagawa N et al (2013) New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. J Thorac Oncol 8(5):612–618

    Article  Google Scholar 

  14. 14.

    Blomberg OS, Spagnuolo L, de Visser KE (2018) Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Dis Model Mech 11(10):dmm036236. https://doi.org/10.1242/dmm.036236

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Mansfield AS et al (2016) Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res 22(9):2177–2182

    CAS  Article  Google Scholar 

  16. 16.

    Hirsch FR et al (2017) PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12(2):208–222

    Article  Google Scholar 

  17. 17.

    Hellmann MD et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41

    CAS  Article  Google Scholar 

  18. 18.

    Krzywinski M et al (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19(9):1639–1645

    CAS  Article  Google Scholar 

  19. 19.

    Ng Kee Kwong F et al (2018) Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas. Histopathology. 72(6):1024–1032

    Article  Google Scholar 

  20. 20.

    Terra S et al (2017) Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. Oncoimmunology 6(11):e1356146

    Article  Google Scholar 

  21. 21.

    Terra S et al (2019) Heterogeneity of programmed death-ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences. Histopathology 74(2):364–367

    Article  Google Scholar 

  22. 22.

    Ilie M et al (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147–153

    CAS  Article  Google Scholar 

  23. 23.

    Mansfield AS et al (2016) Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 27(10):1953–1958

    CAS  Article  Google Scholar 

  24. 24.

    Miyazawa T et al (2019) PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes. Ann Thorac Cardiovasc Surg 25(1):1–9

    Article  Google Scholar 

  25. 25.

    Naso JR et al (2020) Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype. Histopathology 76(3):394–403

    Article  Google Scholar 

  26. 26.

    Jiang X et al (2019) Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 18(1):10

    Article  Google Scholar 

  27. 27.

    Mansfield AS et al (2018) Contraction of T cell richness in lung cancer brain metastases. Sci Rep 8(1):2171

    Article  Google Scholar 

  28. 28.

    Yu H et al (2016) PD-L1 expression in lung cancer. J Thorac Oncol 11(7):964–975

    Article  Google Scholar 

  29. 29.

    Adam J et al (2018) Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol 29(4):953–958

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Aaron S. Mansfield.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hazim, A., Majithia, N., Murphy, S.J. et al. Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas. Cancer Immunol Immunother (2021). https://doi.org/10.1007/s00262-021-02883-x

Download citation

Keywords

  • PD-L1
  • Invasive
  • Lepidic
  • Adenocarcinoma
  • Lung